Insulin Glargine Market, By Type (Lantus, Basaglar, Toujeo, Soliqua/Suliqua, Others), By Diabetes Type (Type 2 Diabetes, Type 1 Diabetes), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Mar 2024

Code : CMI5231

Pages :167

Formats :

Excel and PDF

Industry : Pharmaceutical

Key Developments

In March 2023, Sanofi, a pharmaceutical and healthcare company, stated that it will reduce the list price of Lantus (insulin glargine injection) 100 Units/mL, its most commonly prescribed insulin in the U.S., by 78%. The company will also set a USD 35 out-of-pocket cost cap for Lantus for all patients with commercial insurance, demonstrating its long-standing commitment to providing affordable access to medicines.
In July 2021, Biocon Biologics Ltd., a biopharmaceutical company and Viatris Inc., a global pharmaceutical company announced that Semglee (insulin glargine-yfgn injectable) had been approved by the United States Food and Drug Administration (FDA) as the first interchangeable biosimilar under the 351(k) regulatory pathway.
In August 2020, Mylan N.V. (acquired by Viatris Inc.) and Biocon Biologics India Ltd., a subsidiary of Biocon Ltd., announced the U.S. launch of Semglee (insulin glargine injection) in vial and pre-filled pen presentations, which is approved to help control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes.